Financial Performance - The company's revenue for Q1 2024 was ¥377,460,431.51, a decrease of 1.56% compared to ¥383,440,937.44 in the same period last year[6] - Net profit attributable to shareholders was ¥49,485,359.20, down 14.32% from ¥57,755,969.84 year-on-year[6] - Basic earnings per share decreased to ¥0.25, a decline of 13.79% from ¥0.29 in the previous year[6] - Total operating revenue for Q1 2024 was CNY 377,460,431.51, a decrease of 1.5% compared to CNY 383,440,937.44 in Q1 2023[22] - Net profit for Q1 2024 was CNY 49,485,359.20, down 14.3% from CNY 57,755,961.44 in the same period last year[23] - The total comprehensive income for the first quarter of 2024 was CNY 49,626,884.56, a decrease from CNY 56,505,995.48 in the same period last year, representing a decline of approximately 12.5%[24] Cash Flow - The net cash flow from operating activities was ¥55,330,257.73, down 26.24% from ¥75,015,353.97 in the same period last year[6] - The company's cash and cash equivalents were CNY 792,815,660.74, down from CNY 988,200,226.50, a decrease of approximately 19.7%[20] - Cash inflow from investment activities totaled CNY 478,661,207.44, significantly higher than CNY 119,249,255.06 in the previous year, marking an increase of about 301.5%[27] - The net cash flow from investment activities was CNY 68,930,043.73, a substantial improvement from a negative CNY 539,946,998.48 in the same period last year[27] - Cash and cash equivalents at the end of the period were CNY 440,098,278.17, down from CNY 820,190,549.66 at the end of the previous year, representing a decrease of approximately 46.4%[27] - Total cash outflow from operating activities was CNY 409,432,971.35, compared to CNY 352,108,930.74 in the previous year, indicating an increase of approximately 16.3%[27] - The company incurred a cash outflow of CNY 196,106,641.68 from financing activities, a significant increase from CNY 62,089,206.73 in the previous year, representing an increase of about 215.5%[27] Assets and Liabilities - Total assets at the end of the period were ¥4,962,143,722.24, a decrease of 2.78% from ¥5,104,032,178.39 at the end of the previous year[6] - Total liabilities decreased to CNY 2,086,964,595.18 from CNY 2,271,754,945.18, a reduction of about 8.1%[20] - The company’s long-term borrowings were CNY 47,740,277.77, a slight decrease from CNY 50,034,657.53[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 36,447, with no preferred shareholders[11] - The largest shareholder, Yang Minmin, holds 20.69% of shares, amounting to 41,307,019 shares, with 8,300,000 shares pledged[11] - The top 10 shareholders collectively hold a significant portion of the company's shares, with the largest holding being 20.69%[11] - The company reported a total of 5,756,792 shares held by Henan Hengtong Boyuan Venture Capital Partnership, accounting for 2.88% of total shares[12] Revenue Breakdown - Revenue from drug research stage products and services was CNY 85,365,502.77, accounting for 22.62% of total revenue, up 5.45% year-over-year[16] - Revenue from drug development and commercialization stage products and services was CNY 291,938,068.80, down 3.45% from the previous year[16] Operating Costs and Expenses - Total operating costs decreased to CNY 325,204,409.51 from CNY 344,985,836.29, reflecting a reduction of approximately 5.8%[22] - Research and development expenses were CNY 34,513,051.40, a decrease of 28.6% compared to CNY 48,393,224.73 in Q1 2023[23] - The company reported a gross profit margin of 13.8% for Q1 2024, compared to 10.0% in Q1 2023[22] Taxation - The company recorded a 54.13% increase in taxes and surcharges, amounting to ¥5,103,201.63, in line with the company's expanded scale[9] - The company experienced a 68.07% decrease in tax refunds received, totaling ¥9,329,340.32, due to reduced export tax rebates[10]

2023 年，公司董事会严格按照《公司法》《证券法》等法律法规以及《公司 章程》等规章制度的规定，切实履行股东大会赋予的董事会职责，勤勉尽责地开 展各项工作，促进公司持续、健康、稳定的发展。现将公司董事会 2023 年工作 情况汇报如下： 一、 2023 年公司经营情况概述 公司"以分子砌块为抓手，以化学和技术创新为驱动，全程服务药物发现、 开发到商业化"的一体化战略，持续巩固分子砌块业务技术优势，完善药物发现 技术服务平台，进一步夯实 CRDMO 业务布局，不断加强各个业务模块和技术平台 能力建设，搭建有特色和差异化的药物研发和生产的服务平台。 报告期内，面对宏观经济环境波动以及生物医药投融资下滑对需求端的影响， 公司不断提高技术能力，增强经营的确定性，报告期内公司实现营业收入 17.25 亿元，较去年同期增长 8.18%。由于公司目前仍处于能力建设阶段，固定资产折 旧规模较大，当期折旧金额 1.09 亿元，较去年同期增长 34.06%。公司持续优化 人才结构，提升对高素质人才的吸引力，人员规模和薪资待遇较去年同期有一定 增长，人力资源支出 5.95 亿元，较去年同期增长 0.81 亿元，增幅 15.77% ...

| 章程修改前后对照表 | | | --- | --- | | 原《南京药石科技股份有限公司章程》内容 | 修改后《南京药石科技股份有限公司章程》内容 | | 第七条 公司注册资本为人民币 19,966.4344 万 | 第七条 公司注册资本为人民币 19,966.4658 | | 元。 | 万元。 | | 公司因增加或减少注册资本而导致注册资本总 | 公司因增加或减少注册资本而导致注册资本 | | 额变更的，可以在股东大会通过同意增加或减少注册 | 总额变更的，可以在股东大会通过同意增加或减少 | | 资本决议后，再就因此需要修改公司章程的事项通过 | 注册资本决议后，再就因此需要修改公司章程的事 | | 一项决议，并说明授权董事会具体办理注册资本的变 | 项通过一项决议，并说明授权董事会具体办理注册 | | 更登记手续。 | 资本的变更登记手续。 | | 第十五条 经依法登记，公司的经营范围是：生 | 第十五条 经依法登记，公司的经营范围是：生 | | 物医药专业领域内的技术开发、技术咨询、技术服务、 | 物医药专业领域内的技术开发、技术咨询、技术服 | | 技术转让；生物医药中间体（除药品）研发、生产、 ...

（2024 年 4 月修订） 第一章 总 则 战略与 ESG 委员会工作 南 京 药 石 科 技 股 份 有 限 公 司 战 略 与 ESG 委 员 会 工 作 制 度 第一条 为适应南京药石科技股份有限公司（以下简称"公司"）战略发展需要， 增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加强决策科学性， 提高重大投资决策的效益和决策的质量，完善公司治理结构，提升公司环境、社会 及公司治理（ESG）能力及可持续发展绩效，实现公司可持续发展目标，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》等有关国家 法律、法规、规范性文件以及《南京药石科技股份有限公司章程》（以下简称"《公 司章程》"）的规定，公司设置战略与 ESG 委员会，并制订本工作制度。 第二条 战略与 ESG 委员会是公司在董事会中设置的专门工作机构，主要负责 对公司长期发展战略和重大投资决策进行研究并提出建议，拟定公司的可持续发展 目标和发展规划，对公司可持续发展和 ESG 管理重要事项进行评估并对其实施进 行监督，对董事会负责并报告工作。 第二章 人员组成 第三条 战略与 ESG 委员会成员由不少于三名董 ...

Financial Performance - The company's operating revenue for 2023 was ¥1,725,203,986.49, an increase of 8.18% compared to ¥1,594,699,978.41 in 2022[24]. - The net profit attributable to shareholders decreased by 37.19% to ¥197,360,947.76 from ¥314,223,824.02 in the previous year[24]. - The basic earnings per share fell by 37.34% to ¥0.99, down from ¥1.58 in 2022[24]. - The total assets at the end of 2023 were ¥5,104,032,178.39, reflecting a growth of 4.97% from ¥4,862,189,119.46 in 2022[24]. - The net cash flow from operating activities was ¥246,839,976.80, a slight increase of 0.09% compared to ¥246,608,762.55 in 2022[24]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was ¥176,044,097.89, down 33.81% from ¥265,972,288.46 in 2022[24]. - The weighted average return on equity decreased to 7.16% from 12.44% in the previous year, a decline of 5.28%[24]. - The company experienced a decline in net profit for the third quarter of 2023, reporting ¥40,155,270.39 compared to ¥56,135,029.49 in the second quarter[28]. - The company achieved revenue of 1.725 billion yuan, an increase of 8.18% year-on-year[64]. - The net profit attributable to shareholders decreased to 197 million yuan, a year-on-year decline of 37.19%[64]. - The total revenue for 2023 reached ¥1,725,203,986.49, representing an 8.18% increase compared to ¥1,594,699,978.41 in 2022[91]. Investment and Cash Management - The company plans to use up to CNY 50,000,000 of temporarily idle raised funds for cash management without affecting normal operations[118]. - The total investment amount for the reporting period was CNY 942,274,358.30, representing a 53.48% increase compared to CNY 613,950,404.97 in the same period last year[109]. - The company raised a net amount of RMB 928,090,177.20 from the issuance of shares, with actual usage of RMB 37,483,455.26 during the reporting period, and a cumulative usage of RMB 530,329,334.17 as of December 31, 2023[119]. - The company has completed the use of all funds raised from the issuance of convertible bonds in 2022[125]. - The company has utilized 40,103.10 million of temporarily idle raised funds for purchasing low-risk financial products as of December 31, 2023[125]. Research and Development - R&D expenses amounted to 169 million yuan, with a R&D expense ratio of 9.81%, maintaining a high level in the industry[64]. - The company synthesized over 6,000 new molecular building blocks during the reporting period[70]. - The company is focusing on the development of high-end injectable formulations, which have longer development cycles[127]. - The company aims to enhance its capabilities in drug development and commercialization through innovative chemical technologies and new drug molecule designs[100]. - The company is increasing R&D investment and expanding its business chain to enhance its technical and service capabilities, thereby improving market competitiveness[137]. Market and Industry Trends - In 2023, global pharmaceutical R&D spending reached $161 billion, with R&D investment accounting for 23.4% of sales revenue, an increase of 4.6 percentage points from 2022[35]. - The number of new drugs launched globally in 2023 was 69, a 10% increase from 2022, with over 40% classified as "first-in-class" therapies, primarily in oncology (30%) and neurology (17%)[35]. - Emerging biotech companies contributed to 56% of new drugs launched in 2023, highlighting their role as innovation engines in the pharmaceutical market[36]. - China's share of global clinical pipelines rose from 3% a decade ago to 28% in 2023, with over 30 new drugs launched annually for six consecutive years[37]. - The Chinese CDMO market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% over the next five years, double the global growth rate, increasing its share of the global market from 11% in 2021 to 16% by 2025[37]. Corporate Governance - The company has a governance structure that complies with legal requirements, ensuring effective decision-making and operational independence from its controlling shareholders[147]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[148]. - The company has established an independent financial department with specialized personnel, ensuring financial operations are separate from controlling shareholders[149]. - The company has a well-defined corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent management[149]. - The company has engaged in multiple investor communications, with 248 participants in April 2023 and 68 in October 2023, discussing its annual and quarterly performance[141]. Risk Management - The company faces potential risks including a decline in drug research market demand, changes in industry policies, intensified market competition, and quality control risks[3]. - The company emphasizes the importance of maintaining awareness of investment risks related to forward-looking statements in the annual report[3]. - The company actively tracks regulatory changes in the pharmaceutical industry to adjust its operational strategies accordingly, minimizing adverse impacts from policy shifts[138]. - The company has not experienced major safety or environmental incidents, but it continues to invest in environmental protection and safety production measures as its business scales[139]. Employee and Talent Management - The total number of employees at the end of the reporting period was 2,455, with 1,351 in the parent company and 1,104 in major subsidiaries[184]. - The company employed 1,492 technical personnel, representing approximately 60.8% of the total workforce[184]. - The company has a total of 119 employees with a doctoral degree, contributing to its strong technical capabilities[185]. - The company's compensation policy includes a fixed salary and a variable salary based on project progress and individual performance, ensuring internal fairness and external competitiveness[186]. - The company has designed both technical and management promotion channels to offer employees good career development opportunities[186]. Strategic Initiatives - The company is committed to optimizing operational costs and improving profitability through lean operations and effective resource allocation[136]. - The company plans to implement advanced technologies such as continuous flow chemistry and biocatalysis to reduce project costs and enhance market competitiveness[135]. - The company aims to leverage its experienced management team to drive innovation and operational efficiency in the coming years[156]. - The company anticipates continued growth in revenue and market share as it implements its strategic initiatives[156]. - The company is actively investing in new technologies to improve its product pipeline and meet evolving market demands[156].

南京药石科技股份有限公司 章 程 二0 二四年四月 | 第一章 总则 | 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 股份 | 4 | | 第一节 | 股份发行 4 | | | - 5 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 6 | | 第四章 | 股东和股东大会 7 | | 第一节 | 股东 7 | | 第二节 | 股东大会的一般规定 9 | | 第三节 | 股东大会的召集 13 | | 第四节 | 股东大会的提案与通知 14 | | 第五节 | 股东大会的召开 16 | | 第六节 | 股东大会的表决和决议 18 | | 第五章 | 董事会 23 | | 第一节 | 董事 23 | | 第二节 | 独立董事 25 | | 第三节 | 董事会 27 | | 第四节 | 董事会专门委员会 30 | | 第六章 | 总经理及其他高级管理人员 32 | | 第七章 | 监事会 34 | | 第一节 | 监事 34 | | 第二节 | 监事会 35 | | 第八章 | 财务会计制度、利润分配和审计 36 | | 第一节 | 财务会计制度 36 ...

南京药石科技股份有限公司 第三条 公司聘任或解聘会计师事务所，应当经公司董事会审计委员会（以下 简称"审计委员会"）审议同意后，提交董事会审议，并由股东大会决定。选聘 结果未出前，公司不能聘请会计师事务所开展审计业务。 第四条 公司控股股东、实际控制人不得向公司指定会计师事务所，也不得干 预审计委员会独立履行审核职责。 第二章 会计师事务所执业质量要求 第五条 公司选聘的会计师事务所应当具备以下资格： （一）具有独立的法人资格，具备国家行业主管部门和中国证监会规定的开 展证券期货相关业务所需的执业资格； 会计师事务所选聘制度 （2024 年 4 月） 第一章 总则 第一条 为规范南京药石科技股份有限公司（以下简称"公司"）选聘（含续 聘）会计师事务所相关行为，切实维护股东利益，保证财务信息的真实性和连续 性，支持会计师事务所依法公正执业，根据《中华人民共和国公司法》《中华人 民共和国证券法》《深圳证券交易所创业板股票上市规则》《国有企业、上市公 司选聘会计师事务所管理办法》等相关法律法规和规范性文件，并结合公司实际 情况，特制定本制度。 第二条 公司聘任会计师事务所对财务会计报告发表审计意见、出具审计报 告， ...

独 立 董 事 关 于 控 股 股 东 及 其 他 关 联 方 占 用 公 司 资 金 、 公 司 对 外 担 保 情 况 的 专 项 说 明 和 独 立 意 见 南 京 药 石 科 技 股 份 有 限 公 司 独立董事（签名）： 作为南京药石科技股份有限公司（以下简称"公司"）的独立董事，根据中 国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》（证监会公告〔2022〕26 号）《公司章程》《独立董事工作制度》等有关规定， 本着对公司、全体股东和投资者负责的态度，秉持实事求是的原则，基于独立判 断，对公司截至 2023 年 12 月 31 日控股股东及其他关联方是否占用公司资金的 情况、公司对外担保情况进行了认真细致的核查，现就上述事项发表独立意见如 下： 一、 关于控股股东及其他关联方占用公司资金情况的说明及独立意见 我们阅读了公司提供的相关资料，基于客观、独立的判断，对报告期内公司 控股股东及其他关联方占用公司资金情况进行专项说明并发表独立意见如下： 报告期内，公司与控股股东及其关联方之间不存在非经营性占用资金的情况。 报告期内，公司与关联方之间的资金往来属于正常的经营性关 ...

南 京 药 石 科 技 股 份 有 限 公 司 董 事 会 审 计 委 员 会 对 会 计 师 事 务 所 2 0 2 3 年度履职情况 评 估 及 履 行 监 督 职 责 情 况 的 报 告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》等规定和 要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事 会审计委员会对会计师事务所 2023 年度履职评估及履行监督职责的情况汇报如 下： 一、 2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 公证天业会计师事务所（特殊普通合伙）（以下简称"公证天业"），创立于 1982 年，是全国首批经批准具有从事证券、期货相关业务资格及金融业务审计 资格的会计师事务所之一。2013 年 9 月 18 日，转制为特殊普通合伙企业。截止 2023 年 12 月 31 日，公证天业合伙人数量 58 人，员工 884 人，其中：注册会计 师 334 人，员工中审计业务人员 830 人。 （ ...

华泰联合证券有限责任公司 关于南京药石科技股份有限公司 2023 年度募集资金存放与实际使用情况的专项核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"、"保荐机构"）作为 南京药石科技股份有限公司（以下简称"药石科技"、"公司"）2020年度向特 定对象发行股票、2022年度向不特定对象发行可转换公司债券的保荐机构，根据 《证券发行上市保荐业务管理办法》《上市公司监管指引第2号—上市公司募集 资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第2号— 创业板上市公司规范运作》等有关法律法规规定，对药石科技2023年度募集资金 存放与实际使用情况进行了核查，具体如下： 一、募集资金基本情况 （一）2020 年向特定对象发行股票募集资金 2、募集资金使用及结余情况 报告期内，公司实际使用募集资金37,483,455.26元。截止2023年12月31日， 公司累计使用募集资金530,329,334.17元,其中项目投入募集资金250,856,868.50 元，补充流动资金279,472,465.67元（含销户转出用于一般补流金额16,397.90元）； 累计收到理财收益21,689,888.73 ...